PARP inhibitors: New tools to protect from inflammation

Biochemical Pharmacology

Volumn 80, Issue 12, 2010, Pages 1869-1877

  Giansanti, Vincenzo ^a   Donà, Francesca ^a   Tillhon, Micol ^a   Scovassi, A Ivana ^a  

^a CNR   (Italy)

Author keywords

Inflammation; Necrosis; NF B; PARP; ROS

Indexed keywords

1,5 DIHYDROXYISOQUINOLINE; 2 [2 (1 PIPERIDINYL)ETHYLTHIO] 4(3H) QUINAZOLINONE; 3 AMINOBENZAMIDE; 4 AMINO 1,8 NAPHTALIMIDE; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; ADENOSINE DIPHOSPHATE RIBOSE; BENZAMIDE; DR 2313; GPI 15; GPI 15427; INO 1001; INO 1153; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NU 1085; ONO 1924H; POLY(ADENOSINE DIPHOSPHATE RIBOSE); UNCLASSIFIED DRUG;

ADENOSINE DIPHOSPHATE RIBOSYLATION; CELL DAMAGE; DIABETES MELLITUS; DNA DAMAGE; DRUG ACTIVITY; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; ENZYME ACTIVATION; HUMANS; INFLAMMATION; POLY(ADP-RIBOSE) POLYMERASES;

EID: 78049414814     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.04.022     Document Type: Review

References (161)

1. Altmeyer M., Messner S., Hassa P.O., Fey M., Hottiger M.O. Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites. Nucleic Acids Res 2009, 37:3723-3738.
2. Haenni S.S., Hassa P.O., Altmeyer M., Fey M., Imhof R., Hottiger M.O. Identification of lysines 36 and 37 of PARP-2 as targets for acetylation and auto-ADP-ribosylation. Int J Biochem Cell Biol 2008, 40:2274-2283.
3. Hassa P.O., Haenni S.S., Elser M., Hottiger M.O. Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going?. Microbiol Mol Biol Rev 2006, 70:789-829.
4. Schreiber V., Dantzer F., Ame J.C., de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006, 7:517-528.
5. Ame J.C., Spenlehauer C., de Murcia G. The PARP superfamily. Bioessays 2004, 26:882-893.
6. Frouin I., Scovassi A.I. Poly(ADP-ribosylation) regulates DNA replication and repair. DNA replication, repair and recombination at the crossroad between genome integrity and genome instability: a biochemical perspective 2008, 115-130. Research Signpost, Kerala, India. G. Maga (Ed.).
7. Hakme A., Wong H.K., Dantzer F., Schreiber V. The expanding field of poly(ADP-ribosyl)ation reactions. EMBO Rep 2008, 9:1094-1100.
8. Hassa P.O., Hottiger M.O. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci 2008, 13:3046-3082.
9. Nguewa P.A., Fuertes M.A., Valladares B., Alonso C., Perez J.M. Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications. Prog Biophys Mol Biol 2005, 88:143-172.
10. Hottiger M.O., Hassa P.O., Luscher B., Schuler H., Koch-Nolte F. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem Sci 2010, 35:208-219.
11. Gagne J.P., Hendzel M.J., Droit A., Poirier G.G. The expanding role of poly(ADP-ribose) metabolism: current challenges and new perspectives. Curr Opin Cell Biol 2006, 18:145-151.
12. Kim M.Y., Zhang T., Kraus W.L. Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal. Genes Dev 2005, 19:1951-1967.
13. Petermann E., Keil C., Oei S.L. Importance of poly(ADP-ribose) polymerases in the regulation of DNA-dependent processes. Cell Mol Life Sci 2005, 62:731-738.
14. Rouleau M., Aubin R.A., Poirier G.G. Poly(ADP-ribosyl)ated chromatin domains: access granted. J Cell Sci 2004, 117:815-825.
15. Wacker D.A., Frizzell K.M., Zhang T., Kraus W.L. Regulation of chromatin structure and chromatin-dependent transcription by poly(ADP-ribose) polymerase-1: possible targets for drug-based therapies. Subcell Biochem 2007, 41:45-69.
16. Kraus W.L. Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation. Curr Opin Cell Biol 2008, 20:294-302.
17. Caiafa P., Guastafierro T., Zampieri M. Epigenetics: poly(ADP-ribosyl)ation of PARP-1 regulates genomic methylation patterns. FASEB J 2009, 23:672-678.
18. Shieh W.M., Ame J.C., Wilson M.V., Wang Z.Q., Koh D.W., Jacobson M.K., et al. Poly(ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymers. J Biol Chem 1998, 273:30069-30072.
19. Burkle A. DNA repair and PARP in aging. Free Radic Res 2006, 40:1295-1302.
20. Jeggo P.A. DNA repair: PARP - another guardian angel?. Curr Biol 1998, 8:R49-R51.
21. Tong W.M., Cortes U., Wang Z.Q. Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis. Biochim Biophys Acta 2001, 1552:27-37.
22. Woodhouse B.C., Dianov G.L. Poly ADP-ribose polymerase-1: an international molecule of mystery. DNA Repair 2008, 7:1077-1086.
23. Scovassi A.I. The poly(ADP-ribosylation) story: a long route from Cinderella to Princess. Riv Biol 2007, 100:351-360.
24. Scovassi A.I., Denegri M., Donzelli M., Rossi L., Bernardi R., Mandarino A., et al. Poly(ADP-ribose) synthesis in cells undergoing apoptosis: an attempt to face death before PARP degradation. Eur J Histochem 1998, 42:251-258.
25. Scovassi A.I., Poirier G.G. Poly(ADP-ribosylation) and apoptosis. Mol Cell Biochem 1999, 199:125-137.
26. Soldani C., Lazzè M.C., Bottone M.G., Tognon G., Biggiogera M., Pellicciari C.E., et al. Poly(ADP-ribose) polymerase cleavage during apoptosis: when and where?. Exp Cell Res 2001, 269:193-201.
27. Soldani C., Scovassi A.I. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 2002, 7:321-328.
28. Scovassi A.I., Diederich M. Modulation of poly(ADP-ribosylation) in apoptotic cells. Biochem Pharmacol 2004, 68:1041-1047.
29. Wang Y., Dawson V.L., Dawson T.M. Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp Neurol 2009, 218:193-202.
30. David K.K., Andrabi S.A., Dawson T.M., Dawson V.L. Parthanatos, a messenger of death. Front Biosci 2009, 14:1116-1128.
31. Munoz-Gamez J.A., Rodriguez-Vargas J.M., Quiles-Perez R., Aguilar-Quesada R., Martin-Oliva D., de Murcia G., et al. PARP-1 is involved in autophagy induced by DNA damage. Autophagy 2009, 5:61-74.
32. Hauschildt S., Scheipers P., Bessler W., Schwarz K., Ullmer A., Flad H.D., et al. Role of ADP-ribosylation in activated monocytes/macrophages. Adv Exp Med Biol 1997, 419:249-252.
33. Szabo C., Lim L.H., Cuzzocrea S., Getting S.J., Zingarelli B., Flower R.J., et al. Inhibition of poly (ADP-ribose) synthetase attenuates neutrophil recruitment and exerts antiinflammatory effects. J Exp Med 1997, 186:1041-1049.
34. Ghosh S., May M.J., Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998, 16:225-260.
35. Karin M., Delhase M. JNK or IKK, AP-1 or NF-kappaB, which are the targets for MEK kinase 1 action?. Proc Natl Acad Sci USA 1998, 95:9067-9069.
36. Hassa P.O., Buerki C., Lombardi C., Imhof R., Hottiger M.O. Transcriptional coactivation of nuclear factor-kappaB-dependent gene expression by p300 is regulated by poly(ADP)-ribose polymerase-1. J Biol Chem 2003, 278:45145-45153.
37. Hassa P.O., Haenni S.S., Buerki C., Meier N.I., Lane W.S., Owen H., et al. Acetylation of poly(ADP-ribose) polymerase-1 by p300/CREB-binding protein regulates coactivation of NF-kappaB-dependent transcription. J Biol Chem 2005, 280:40450-40464.
38. Messner S., Schuermann D., Altmeyer M., Kassner I., Schmidt D., Schar P., et al. Sumoylation of poly(ADP-ribose) polymerase 1 inhibits its acetylation and restrains transcriptional coactivator function. FASEB J 2009, 23:3978-3989.
39. Hassa P.O., Covic M., Bedford M.T., Hottiger M.O. Protein arginine methyltransferase 1 coactivates NF-kappaB-dependent gene expression synergistically with CARM1 and PARP1. J Mol Biol 2008, 377:668-678.
40. Beneke S. Poly(ADP-ribose) polymerase activity in different pathologies-the link to inflammation and infarction. Exp Gerontol 2008, 43:605-614.
41. Haddad M., Rhinn H., Bloquel C., Coqueran B., Szabo C., Plotkine M., et al. Anti-inflammatory effects of PJ34, a poly(ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice. Br J Pharmacol 2006, 149:23-30.
42. Huang D., Yang C.Z., Yao L., Wang Y., Liao Y.H., Huang K. Activation and overexpression of PARP-1 in circulating mononuclear cells promote TNF-alpha and IL-6 expression in patients with unstable angina. Arch Med Res 2008, 39:775-784.
43. Jijon H.B., Churchill T., Malfair D., Wessler A., Jewell L.D., Parsons H.G., et al. Inhibition of poly(ADP-ribose) polymerase attenuates inflammation in a model of chronic colitis. Am J Physiol Gastrointest Liver Physiol 2000, 279:G641-G651.
44. Mazzon E., Dugo L., Li J.H., Di Paola R., Genovese T., Caputi A.P., et al. GPI 6150, a PARP inhibitor, reduces the colon injury caused by dinitrobenzene sulfonic acid in the rat. Biochem Pharmacol 2002, 64:327-337.
45. Naura A.S., Datta R., Hans C.P., Zerfaoui M., Rezk B.M., Errami Y., et al. Reciprocal regulation of iNOS and PARP-1 during allergen-induced eosinophilia. Eur Respir J 2009, 33:252-262.
46. Su C.F., Liu D.D., Kao S.J., Chen H.I. Nicotinamide abrogates acute lung injury caused by ischaemia/reperfusion. Eur Respir J 2007, 30:199-204.
47. Elser M., Borsig L., Hassa P.O., Erener S., Messner S., Valovka T., et al. Poly(ADP-ribose) polymerase 1 promotes tumor cell survival by coactivating hypoxia-inducible factor-1-dependent gene expression. Mol Cancer Res 2008, 6:282-290.
48. Suzuki T., Nishi T., Nagino T., Sasaki K., Aizawa K., Kada N., et al. Functional interaction between the transcription factor Kruppel-like factor 5 and poly(ADP-ribose) polymerase-1 in cardiovascular apoptosis. J Biol Chem 2007, 282:9895-9901.
49. Sakamaki J., Daitoku H., Yoshimochi K., Miwa M., Fukamizu A. Regulation of FOXO1-mediated transcription and cell proliferation by PARP-1. Biochem Biophys Res Commun 2009, 382:497-502.
50. Reinemund J., Seidel K., Steckelings U.M., Zaade D., Klare S., Rompe F., et al. Poly(ADP-ribose) polymerase-1 (PARP-1) transcriptionally regulates angiotensin AT2 receptor (AT2R) and AT2R binding protein (ATBP) genes. Biochem Pharmacol 2009, 77:1795-1805.
51. Catalgol B., Wendt B., Grimm S., Breusing N., Ozer N.K., Grune T. Chromatin repair after oxidative stress: role of PARP-mediated proteasome activation. Free Radic Biol Med 2010, 48:673-680.
52. Clark J.B., Ferris G.M., Pinder S. Inhibition of nuclear NAD nucleosidase and poly ADP-ribose polymerase activity from rat liver by nicotinamide and 5'-methyl nicotinamide. Biochim Biophys Acta 1971, 238:82-85.
53. Clark J.B., Pinder S. Control of the steady-state concentrations of the nicotinamide nucleotides in rat liver. Biochem J 1969, 114:321-330.
54. Colyer R.A., Burdette K.E., Kidwell W.R. Poly ADP-ribose synthesis and DNA replication in synchronized mouse L-cells. Biochem Biophys Res Commun 1973, 53:960-966.
55. Purnell M.R., Whish W.J. Novel inhibitors of poly(ADP-ribose) synthetase. Biochem J 1980, 185:775-777.
56. Shall S. Proceedings: experimental manipulation of the specific activity of poly(ADP-ribose) polymerase. J Biochem 1975, 77:2.
57. Ruf A., Mennissier de Murcia J., de Murcia G., Schulz G.E. Structure of the catalytic fragment of poly(AD-ribose) polymerase from chicken. Proc Natl Acad Sci USA 1996, 93:7481-7485.
58. Ruf A., de Murcia G., Schulz G.E. Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling. Biochemistry 1998, 37:3893-3900.
59. Oliver A.W., Ame J.C., Roe S.M., Good V., de Murcia G., Pearl L.H. Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2. Nucleic Acids Res 2004, 32:456-464.
60. Sestili P., Spadoni G., Balsamini C., Scovassi I., Cattabeni F., Duranti E., et al. Structural requirements for inhibitors of poly(ADP-ribose) polymerase. J Cancer Res Clin Oncol 1990, 116:615-622.
61. Skalitzky D.J., Marakovits J.T., Maegley K.A., Ekker A., Yu X.H., Hostomsky Z., et al. Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem 2003, 46:210-213.
62. Tikhe J.G., Webber S.E., Hostomsky Z., Maegley K.A., Ekkers A., Li J., et al. Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase. J Med Chem 2004, 47:5467-5481.
63. Banasik M., Komura H., Shimoyama M., Ueda K. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 1992, 267:1569-1575.
64. Eltze T., Boer R., Wagner T., Weinbrenner S., McDonald M.C., Thiemermann C., et al. Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors. Mol Pharmacol 2008, 74:1587-1598.
65. Wayman N., McDonald M.C., Thompson A.S., Threadgill M.D., Thiemermann C. 5-aminoisoquinolinone, a potent inhibitor of poly (adenosine 5'-diphosphate ribose) polymerase, reduces myocardial infarct size. Eur J Pharmacol 2001, 430:93-100.
66. Zingarelli B., O'Connor M., Hake P.W. Inhibitors of poly (ADP-ribose) polymerase modulate signal transduction pathways in colitis. Eur J Pharmacol 2003, 469:183-194.
67. Giansanti V., Scovassi A.I. Poly(ADP-ribosylation): beneficial effects of its inhibition. Curr Enzyme Inhib 2009, 5:99-109.
68. Jagtap P.G., Baloglu E., Southan G.J., Mabley J.G., Li H., Zhou J., et al. Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem 2005, 48:5100-5103.
69. Peralta-Leal A., Rodriguez-Vargas J.M., Aguilar-Quesada R., Rodriguez M.I., Linares J.L., de Almodovar M.R., et al. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Free Radic Biol Med 2009, 47:13-26.
70. Curtin N.J. PARP inhibitors for cancer therapy. Expert Rev Mol Med 2005, 7:1-20.
71. Drew Y., Plummer R. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist Updat 2009, 12:153-156.
72. Helleday T., Petermann E., Lundin C., Hodgson B., Sharma R.A. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008, 8:193-204.
73. Lord C.J., Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 2008, 8:363-369.
74. Tentori L., Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 2005, 52:25-33.
75. Tentori L., Graziani G. Recent approaches to improve the antitumor efficacy of temozolomide. Curr Med Chem 2009, 16:245-257.
76. Tentori L., Portarena I., Torino F., Scerrati M., Navarra P., Graziani G. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. Glia 2002, 40:44-54.
77. Durkacz B.W., Omidiji O., Gray D.A., Shall S. (ADP-ribose)n participates in DNA excision repair. Nature 1980, 283:593-596.
78. Almeida K.H., Sobol R.W. A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification. DNA Repair 2007, 6:695-711.
79. Dantzer F., Schreiber V., Niedergang C., Trucco C., Flatter E., De La Rubia G., et al. Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie 1999, 81:69-75.
80. Lavrik O.I., Prasad R., Sobol R.W., Horton J.K., Ackerman E.J., Wilson S.H. Photoaffinity labeling of mouse fibroblast enzymes by a base excision repair intermediate. Evidence for the role of poly(ADP-ribose) polymerase-1 in DNA repair. J Biol Chem 2001, 276:25541-25548.
81. Cazzalini O., Donà F., Savio M., Tillhon M., Maccario C., Perucca P., et al. p21(CDKN1A) participates in base excision repair by regulating the activity of poly(ADP-ribose) polymerase-1. DNA Repair 2010, 10.1016/j.dnarep.2010.02.011.
82. Jelezcova E., Trivedi R.N., Wang X.H., Tang J.B., Brown A.R., Goellner E.M., et al. Parp1 activation in mouse embryonic fibroblasts promotes Pol beta-dependent cellular hypersensitivity to alkylation damage. Mutat Res 2010, 686:57-67.
83. Shall S., de Murcia G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?. Mutat Res 2000, 460:1-15.
84. Esposito E., Cuzzocrea S. Superoxide, NO, peroxynitrite and PARP in circulatory shock and inflammation. Front Biosci 2009, 14:263-296.
85. Szabo C. Poly (ADP-ribose) polymerase activation and circulatory shock. Novartis Found Symp 2007, 280:92-103. [discussion 103-7, 160-4].
86. Pacher P., Szabo C. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev 2007, 25:235-260.
87. Moroni F., Chiarugi A. Post-ischemic brain damage: targeting PARP-1 within the ischemic neurovascular units as a realistic avenue to stroke treatment. FEBS J 2009, 276:36-45.
88. Szabo C. Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications. Pharmacol Res 2005, 52:60-71.
89. Masutani M., Suzuki H., Kamada N., Watanabe M., Ueda O., Nozaki T., et al. Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes. Proc Natl Acad Sci USA 1999, 96:2301-2304.
90. Pieper A.A., Brat D.J., Krug D.K., Watkins C.C., Gupta A., Blackshaw S., et al. Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. Proc Natl Acad Sci USA 1999, 96:3059-3064.
91. Virag L. Poly(ADP-ribosyl)ation in asthma and other lung diseases. Pharmacol Res 2005, 52:83-92.
92. Weseler A.R., Geraets L., Moonen H.J., Manders R.J., van Loon L.J., Pennings H.J., et al. Poly (ADP-ribose) polymerase-1-inhibiting flavonoids attenuate cytokine release in blood from male patients with chronic obstructive pulmonary disease or type 2 diabetes. J Nutr 2009, 139:952-957.
93. Shrikhande G., Khaodhiar L., Scali S., Lima C., Hubbard M., Dudley K., et al. Valsartan improves resting skin blood flow in type 2 diabetic patients and reduces poly(adenosine diphosphate-ribose) polymerase activation. J Vasc Surg 2006, 43:760-770. [discussion 770-1].
94. Yelamos J., Schreiber V., Dantzer F. Toward specific functions of poly(ADP-ribose) polymerase-2. Trends Mol Med 2008, 14:169-178.
95. Ishida J., Yamamoto H., Kido Y., Kamijo K., Murano K., Miyake H., et al. Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling. Bioorg Med Chem 2006, 14:1378-1390.
96. Iwashita A., Hattori K., Yamamoto H., Ishida J., Kido Y., Kamijo K., et al. Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors. FEBS Lett 2005, 579:1389-1393.
97. Pellicciari R., Camaioni E., Costantino G., Formentini L., Sabbatini P., Venturoni F., et al. On the way to selective PARP-2 inhibitors. Design, synthesis, and preliminary evaluation of a series of isoquinolinone derivatives. ChemMedChem 2008, 3:914-923.
98. Moroni F., Formentini L., Gerace E., Camaioni E., Pellegrini-Giampietro D.E., Chiarugi A., et al. Selective PARP-2 inhibitors increase apoptosis in hippocampal slices but protect cortical cells in models of post-ischaemic brain damage. Br J Pharmacol 2009, 157:854-862.
99. Karlberg T., Hammarstrom M., Schutz P., Svensson L., Schuler H. Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888. Biochemistry 2010, 49:1056-1058.
100. Lehtio L., Jemth A.S., Collins R., Loseva O., Johansson A., Markova N., et al. Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J Med Chem 2009, 52:3108-3111.
101. Huang S.M., Mishina Y.M., Liu S., Cheung A., Stegmeier F., Michaud G.A., et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009, 461:614-620.
102. McCabe N., Cerone M.A., Ohishi T., Seimiya H., Lord C.J., Ashworth A. Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. Oncogene 2009, 28:1465-1470.
103. Drew Y., Plummer R. The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer. Curr Opin Obstet Gynecol 2010, 22:67-71.
104. Sandhu S.K., Yap T.A., de Bono J.S. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer 2010, 46:9-20.
105. Yashiroda Y., Okamoto R., Hatsugai K., Takemoto Y., Goshima N., Saito T., et al. A novel yeast cell-based screen identifies flavone as a tankyrase inhibitor. Biochem Biophys Res Commun 2010, 394:569-573.
106. Rouleau M., Patel A., Hendzel M.J., Kaufmann S.H., Poirier G.G. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010, 10:293-301.
107. Hassa P.O. The molecular " Jekyll and Hyde" duality of PARP1 in cell death and cell survival. Front Biosci 2009, 14:72-111.
108. Min W., Wang Z.Q. Poly (ADP-ribose) glycohydrolase (PARG) and its therapeutic potential. Front Biosci 2009, 14:1619-1626.
109. Formentini L., Arapistas P., Pittelli M., Jacomelli M., Pitozzi V., Menichetti S., et al. Mono-galloyl glucose derivatives are potent poly(ADP-ribose) glycohydrolase (PARG) inhibitors and partially reduce PARP-1-dependent cell death. Br J Pharmacol 2008, 155:1235-1249.
110. Uchiumi F., Ikeda D., Tanuma S. Changes in the activities and gene expressions of poly(ADP-ribose) glycohydrolases during the differentiation of human promyelocytic leukemia cell line HL-60. Biochim Biophys Acta 2004, 1676:1-11.
111. Falsig J., Christiansen S.H., Feuerhahn S., Burkle A., Oei S.L., Keil C., et al. Poly(ADP-ribose) glycohydrolase as a target for neuroprotective intervention: assessment of currently available pharmacological tools. Eur J Pharmacol 2004, 497:7-16.
112. Tentori L., Leonetti C., Scarsella M., Muzi A., Vergati M., Forini O., et al. Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. Eur J Cancer 2005, 41:2948-2957.
113. Cuzzocrea S., Mazzon E., Genovese T., Crisafulli C., Min W.K., Di Paola R., et al. Role of poly(ADP-ribose) glycohydrolase in the development of inflammatory bowel disease in mice. Free Radic Biol Med 2007, 42:90-105.
114. Wei G., Wang D., Lu H., Parmentier S., Wang Q., Panter S.S., et al. Intranasal administration of a PARG inhibitor profoundly decreases ischemic brain injury. Front Biosci 2007, 12:4986-4996.
115. Okita N., Ashizawa D., Ohta R., Abe H., Tanuma S.I. Discovery of novel poly(ADP-ribose) glycohydrolase inhibitors by a quantitative assay system using dot-blot with anti-poly(ADP-ribose). Biochem Biophys Res Commun 2010, 392:485-489.
116. Hauser B., Groger M., Ehrmann U., Albicini M., Bruckner U.B., Schelzig H., et al. The parp-1 inhibitor ino-1001 facilitates hemodynamic stabilization without affecting DNA repair in porcine thoracic aortic cross-clamping-induced ischemia/reperfusion. Shock 2006, 25:633-640.
117. Black J.H., Casey P.J., Albadawi H., Cambria R.P., Watkins M.T. Poly adenosine diphosphate-ribose polymerase inhibitor PJ34 abolishes systemic proinflammatory responses to thoracic aortic ischemia and reperfusion. J Am Coll Surg 2006, 203:44-53.
118. Mota R.A., Hernandez-Espinosa D., Galbis-Martinez L., Ordonez A., Minano A., Parrilla P., et al. Poly(ADP-ribose) polymerase-1 inhibition increases expression of heat shock proteins and attenuates heat stroke-induced liver injury. Crit Care Med 2008, 36:526-534.
119. Pacher P., Liaudet L., Mabley J.G., Cziraki A., Hasko G., Szabo C. Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure. Int J Mol Med 2006, 17:369-375.
120. Palfi A., Toth A., Hanto K., Deres P., Szabados E., Szereday Z., et al. PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway. J Mol Cell Cardiol 2006, 41:149-159.
121. Bartha E., Solti I., Kereskai L., Lantos J., Plozer E., Magyar K., et al. PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats. Cardiovasc Res 2009, 83:501-510.
122. von Lukowicz T., Hassa P.O., Lohmann C., Boren J., Braunersreuther V., Mach F., et al. PARP1 is required for adhesion molecule expression in atherogenesis. Cardiovasc Res 2008, 78:158-166.
123. Hans C.P., Zerfaoui M., Naura A.S., Troxclair D., Strong J.P., Matrougui K., et al. Thieno[2,3-c]isoquinolin-5-one, a potent poly(ADP-ribose) polymerase inhibitor, promotes atherosclerotic plaque regression in high-fat diet-fed apolipoprotein E-deficient mice: effects on inflammatory markers and lipid content. J Pharmacol Exp Ther 2009, 329:150-158.
124. Beller C.J., Kosse J., Radovits T., Gero D., Krempien R., Gross M.L., et al. Poly(ADP-ribose) polymerase inhibition combined with irradiation: a dual treatment concept to prevent neointimal hyperplasia after endarterectomy. Int J Radiat Oncol Biol Phys 2006, 66:867-875.
125. Gao L., Kwan J.C., Macdonald P.S., Yang L., Preiss T., Hicks M. Improved poststorage cardiac function by poly (ADP-ribose) polymerase inhibition: role of phosphatidylinositol 3-kinase Akt pathway. Transplantation 2007, 84:380-386.
126. Szabo G., Soos P., Mandera S., Heger U., Flechtenmacher C., Bahrle S., et al. INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation. Shock 2004, 21:426-432.
127. Benko R., Pacher P., Vaslin A., Kollai M., Szabo C. Restoration of the endothelial function in the aortic rings of apolipoprotein E deficient mice by pharmacological inhibition of the nuclear enzyme poly(ADP-ribose) polymerase. Life Sci 2004, 75:1255-1261.
128. Tasatargil A., Dalaklioglu S., Sadan G. Poly(ADP-ribose) polymerase inhibition prevents homocysteine-induced endothelial dysfunction in the isolated rat aorta. Pharmacology 2004, 72:99-105.
129. Kaundal R.K., Shah K.K., Sharma S.S. Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation. Life Sci 2006, 79:2293-2302.
130. Nakajima H., Kakui N., Ohkuma K., Ishikawa M., Hasegawa T. A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats. J Pharmacol Exp Ther 2005, 312:472-481.
131. Kauppinen T.M., Suh S.W., Berman A.E., Hamby A.M., Swanson R.A. Inhibition of poly(ADP-ribose) polymerase suppresses inflammation and promotes recovery after ischemic injury. J Cereb Blood Flow Metab 2009, 29:820-829.
132. Hendryk S., Czuba Z.P., Jedrzejowska-Szypulka H., Szliszka E., Phillips V.A., Threadgill M.D., et al. Influence of 5-aminoisoquinolin-1-one (5-AIQ) on neutrophil chemiluminescence in rats with transient and prolonged focal cerebral ischemia and after reperfusion. J Physiol Pharmacol 2008, 59:811-822.
133. Vagnerova K., Liu K., Ardeshiri A., Cheng J., Murphy S.J., Hurn P.D., et al. Poly (ADP-ribose) polymerase-1 initiated neuronal cell death pathway-do androgens matter?. Neuroscience 2010, 166:476-481.
134. Kumaran D., Udayabanu M., Nair R.U., A R., Katyal A. Benzamide protects delayed neuronal death and behavioural impairment in a mouse model of global cerebral ischemia. Behav Brain Res 2008, 192:178-184.
135. Kamanaka Y., Kondo K., Ikeda Y., Kamoshima W., Kitajima T., Suzuki Y., et al. Neuroprotective effects of ONO-1924H, an inhibitor of poly ADP-ribose polymerase (PARP), on cytotoxicity of PC12 cells and ischemic cerebral damage. Life Sci 2004, 76:151-162.
136. Goebel D.J., Winkler B.S. Blockade of PARP activity attenuates poly(ADP-ribosyl)ation but offers only partial neuroprotection against NMDA-induced cell death in the rat retina. J Neurochem 2006, 98:1732-1745.
137. Uehara N., Miki K., Tsukamoto R., Matsuoka Y., Tsubura A. Nicotinamide blocks N-methyl-N-nitrosourea-induced photoreceptor cell apoptosis in rats through poly (ADP-ribose) polymerase activity and Jun N-terminal kinase/activator protein-1 pathway inhibition. Exp Eye Res 2006, 82:488-495.
138. Martinez-Romero R., Canuelo A., Martinez-Lara E., Javier Oliver F., Cardenas S., Siles E. Poly(ADP-ribose) polymerase-1 modulation of in vivo response of brain hypoxia-inducible factor-1 to hypoxia/reoxygenation is mediated by nitric oxide and factor inhibiting HIF. J Neurochem 2009, 111:150-159.
139. Czapski G.A., Cakala M., Gajkowska B., Strosznajder J.B. Poly(ADP-ribose) polymerase-1 inhibition protects the brain against systemic inflammation. Neurochem Int 2006, 49:751-755.
140. Ilnytska O., Lyzogubov V.V., Stevens M.J., Drel V.R., Mashtalir N., Pacher P., et al. Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy. Diabetes 2006, 55:1686-1694.
141. Sharma S.S., Kumar A., Kaundal R.K. Protective effects of 4-amino1,8-napthalimide, a poly (ADP-ribose) polymerase inhibitor in experimental diabetic neuropathy. Life Sci 2008, 82:570-576.
142. Obrosova I.G., Xu W., Lyzogubov V.V., Ilnytska O., Mashtalir N., Vareniuk I., et al. PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy. Free Radic Biol Med 2008, 44:972-981.
143. Negi G., Kumar A., Sharma S.S. Concurrent targeting of nitrosative stress-PARP pathway corrects functional, behavioral and biochemical deficits in experimental diabetic neuropathy. Biochem Biophys Res Commun 2010, 391:102-106.
144. Chiu J., Farhangkhoee H., Xu B.Y., Chen S., George B., Chakrabarti S. PARP mediates structural alterations in diabetic cardiomyopathy. J Mol Cell Cardiol 2008, 45:385-393.
145. Shevalye H., Stavniichuk R., Xu W., Zhang J., Lupachyk S., Maksimchyk Y., et al. Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model. Biochem Pharmacol 2010, 79:1007-1014.
146. Chiu J., Xu B.Y., Chen S., Feng B., Chakrabarti S. Oxidative stress-induced, poly(ADP-ribose) polymerase-dependent upregulation of ET-1 expression in chronic diabetic complications. Can J Physiol Pharmacol 2008, 86:365-372.
147. Suzuki Y., Masini E., Mazzocca C., Cuzzocrea S., Ciampa A., Suzuki H., et al. Inhibition of poly(ADP-ribose) polymerase prevents allergen-induced asthma-like reaction in sensitized Guinea pigs. J Pharmacol Exp Ther 2004, 311:1241-1248.
148. Oumouna M., Datta R., Oumouna-Benachour K., Suzuki Y., Hans C., Matthews K., et al. Poly(ADP-ribose) polymerase-1 inhibition prevents eosinophil recruitment by modulating Th2 cytokines in a murine model of allergic airway inflammation: a potential specific effect on IL-5. J Immunol 2006, 177:6489-6496.
149. Naura A.S., Hans C.P., Zerfaoui M., You D., Cormier S.A., Oumouna M., et al. Post-allergen challenge inhibition of poly(ADP-ribose) polymerase harbors therapeutic potential for treatment of allergic airway inflammation. Clin Exp Allergy 2008, 38:839-846.
150. Di Paola R., Mazzon E., Xu W., Genovese T., Ferrraris D., Muia C., et al. Treatment with PARP-1 inhibitors, GPI 15427 or GPI 16539, ameliorates intestinal damage in rat models of colitis and shock. Eur J Pharmacol 2005, 527:163-171.
151. Sanchez-Fidalgo S., Villegas I., Martin A., Sanchez-Hidalgo M., Alarcon de la Lastra C. PARP inhibition reduces acute colonic inflammation in rats. Eur J Pharmacol 2007, 563:216-223.
152. Quiles-Perez R., Munoz-Gamez J.A., Ruiz-Extremera A., O'Valle F., Sanjuan-Nunez L., Martin-Alvarez A.B., et al. Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression. Hepatology 2010, 51:255-266.
153. Mazzon E., Genovese T., Di Paola R., Muia C., Crisafulli C., Malleo G., et al. Effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase, in a mouse model of acute pancreatitis induced by cerulein. Eur J Pharmacol 2006, 549:149-156.
154. Aydin S., Isik A.T., Cinar E., Demir O., Akay C., Ozyurt M., et al. Does the 3-aminobenzamide effect on bacterial translocation affect experimental acute necrotizing pancreatitis?. Turk J Gastroenterol 2009, 20:20-26.
155. Dalaklioglu S., Tekcan M., Gungor N.E., Celik-Ozenci C., Aksoy N.H., Baykal A., et al. Role of the poly(ADP-ribose)polymerase activity in vancomycin-induced renal injury. Toxicol Lett 2010, 192:91-96.
156. Yam-Canul P., Chirino Y.I., Sanchez-Gonzalez D.J., Martinez-Martinez C.M., Cruz C., Pedraza-Chaverri J. PJ34, a poly adenosine diphosphate-ribose polymerase inhibitor, attenuates chromate-induced nephrotoxicity. Basic Clin Pharmacol Toxicol 2008, 102:483-488.
157. Korkmaz A., Kurt B., Yildirim I., Basal S., Topal T., Sadir S., et al. Effects of poly(ADP-ribose) polymerase inhibition in bladder damage caused by cyclophosphamide in rats. Exp Biol Med 2008, 233:338-343.
158. Kendirci M., Zsengeller Z., Bivalacqua T.J., Gur S., Usta M.F., Chen M., et al. Poly(Adenosine diphosphate-ribose) polymerase inhibition preserves erectile function in rats after cavernous nerve injury. J Urol 2005, 174:2054-2059.
159. Di Paola R., Mazzon E., Muia C., Terrana D., Greco S., Britti D., et al. 5-Aminoisoquinolin-1(2H)-one, a water-soluble poly (ADP-ribose) polymerase (PARP) inhibitor reduces the evolution of experimental periodontitis in rats. J Clin Periodontol 2007, 34:95-102.
160. Genovese T., Mazzon E., Muia C., Patel N.S., Threadgill M.D., Bramanti P., et al. Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and secondary damage in experimental spinal cord trauma. J Pharmacol Exp Ther 2005, 312:449-457.
161. Gonzalez-Rey E., Martinez-Romero R., O'Valle F., Aguilar-Quesada R., Conde C., Delgado M., et al. Therapeutic effect of a poly(ADP-ribose) polymerase-1 inhibitor on experimental arthritis by downregulating inflammation and Th1 response. PLoS One 2007, 2:e1071.